研究显示 asciminib 一周内抑制 CML 驱动蛋白的强度高于 imatinib 与 nilotinib
New leukemia drug suppresses cancer-driving protein more strongly than existing treatments within one week
阿德莱德大学与 SAHMRI 团队在 Leukemia 发表研究,通过直接测量患者血细胞内的 BCR::ABL1 激酶抑制,发现 asciminib 在一周内对 CML 驱动蛋白的抑制强度明显高于 imatinib 和 nilotinib。
研究用直接测量 BCR::ABL1 激酶抑制的方法比较三种 TKI,为早期判断 CML 患者应答提供可参考的检测思路。
A more effective and better-tolerated treatment for chronic myeloid leukemia (CML) could improve quality of life for people living with the disease. A new study led by Adelaide University and the South Australian Health and Medical Research Institute (SAHMRI) has provided the first direct evidence that a targeted therapy can rapidly and consistently suppress the molecular signals that drive CML.
The researchers compared the blocking ability of a new therapy called asciminib with commonly used tyrosine kinase inhibitor (TKI) medications, imatinib and nilotinib. These existing medications have helped many CML patients manage their disease for the past two decades. The findings are published in the journal Leukemia.
"We found asciminib was much more powerful at suppressing the cancer-driving protein that causes the leukemia cells to spread," said associate professor Chung Hoow Kok from Adelaide University's Center for Cancer Biology and SA Pathology.
"This is a huge step forward in the search for better, frontline treatment options for patients who don't respond to current medications. Currently, 25% of patients will develop resistance or intolerance to existing treatments."
To test the potency of the drug, researchers developed a new way to measure how effectively the treatment switches off the cancer-driving protein inside patients' blood cells.
"Within just one week, asciminib achieved substantially stronger suppression of the cancer-driving protein than the currently available treatments," said Adelaide University professor Tim Hughes, who is the leader of SAHMRI's Chronic Myeloid Leukemia Group.
"Importantly, none of the patients experienced the poorer responses sometimes seen with the existing drugs.
"This new biological evidence from our research supports the excellent clinical outcomes from recent trials of asciminib."
Researchers also investigated if asciminib worked in patients who had a specific genetic mutation, which is known to increase the risk of treatment failure. They found the medication was still able to block the main driver of abnormal cell growth, but noted other factors may still affect patient outcomes.
There are more than 7,000 people living with CML in Australia. A type of blood cancer, it is caused by a genetic abnormality which fuels the growth of abnormal blood cells. Medical advances mean that many patients can now manage the potentially life-threatening condition through medication, but only 25% ever reach treatment-free remission.
The findings have been published in the international journal Leukemia and could help doctors identify much earlier whether a patient is responding well to treatment, allowing therapy to be tailored sooner and moving CML care closer to personalized medicine.
"This is an important step toward precision medicine, where treatment decisions are guided by the biology of each patient's cancer rather than a one-size-fits-all approach," said associate professor Kok.
"Our findings reinforce the importance of combining genomic testing with treatment monitoring to work out which patients may benefit from additional therapies or more frequent reviews.
"Our goal is to move beyond treating all patients in the same way. By understanding the biology of each person's CML, we can work toward selecting the right treatment, for the right patient, at the right time."
Publication details
Chung Hoow Kok et al., Direct measurement of in vivo BCR::ABL1 kinase inhibition reveals stronger potency of asciminib as compared with imatinib and nilotinib, Leukemia (2026). DOI: 10.1038/s41375-026-03002-4
Journal information: Leukemia
Key medical concepts
Clinical categories
Who's behind this story?
Lisa Lock
BA art history, MA material culture. Former museum editor, paramedic, and transplant coordinator. Editing for Science X since 2021. Full profile →
Andrew Zinin
Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →
Citation: New leukemia drug suppresses cancer-driving protein more strongly than existing treatments within one week (2026, October 27) retrieved 27 October 2026 from https://medicalxpress.com/news/2026-10-leukemia-drug-suppresses-cancer-protein.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
来源:Medical Xpress · medicalxpress.com